The in vivo results showed that both 2-DG and rapamycin treatments significantly suppressed tumor growth, but overexpression of NAT10 could weaken the anti-tumor effects caused by 2-DG and rapamycin, as indicated by the decreases in tumor size and weight (Figure S4N, S4O, and S4P). The gene discussed is NAT10; the disease is neoplasm.